KR101578877B1 - ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘 - Google Patents

ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘 Download PDF

Info

Publication number
KR101578877B1
KR101578877B1 KR1020137031899A KR20137031899A KR101578877B1 KR 101578877 B1 KR101578877 B1 KR 101578877B1 KR 1020137031899 A KR1020137031899 A KR 1020137031899A KR 20137031899 A KR20137031899 A KR 20137031899A KR 101578877 B1 KR101578877 B1 KR 101578877B1
Authority
KR
South Korea
Prior art keywords
delete delete
mmol
methyl
alkyl
cyclopenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137031899A
Other languages
English (en)
Korean (ko)
Other versions
KR20130141717A (ko
Inventor
이안 에스. 미첼
제임스 에프. 블레이크
루이 수
니콜라스 씨. 켈런
덩밍 씨아오
키스 리 스펜서
조우지프 알. 벤칙
준 리앙
브라이언 사피나
비롱 장
크리스틴 샤보트
스티븐 두
엘리 엠. 월리스
애너 엘. 밴카
스티븐 티. 슐라츠터
Original Assignee
어레이 바이오파마 인크.
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101578877(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 어레이 바이오파마 인크., 제넨테크, 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20130141717A publication Critical patent/KR20130141717A/ko
Application granted granted Critical
Publication of KR101578877B1 publication Critical patent/KR101578877B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
KR1020137031899A 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘 Active KR101578877B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06
US60/818,718 2006-07-06
PCT/US2007/072885 WO2008006040A1 (en) 2006-07-06 2007-07-05 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127011042A Division KR101495408B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147017714A Division KR20140093291A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Publications (2)

Publication Number Publication Date
KR20130141717A KR20130141717A (ko) 2013-12-26
KR101578877B1 true KR101578877B1 (ko) 2016-02-22

Family

ID=38686743

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020137031899A Active KR101578877B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020147017714A Ceased KR20140093291A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020127011042A Active KR101495408B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020097002395A Active KR101178672B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020157010625A Ceased KR20150051240A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020147017714A Ceased KR20140093291A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020127011042A Active KR101495408B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020097002395A Active KR101178672B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020157010625A Ceased KR20150051240A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Country Status (34)

Country Link
EP (4) EP2402325B1 (https=)
JP (4) JP5266216B2 (https=)
KR (5) KR101578877B1 (https=)
CN (2) CN102816124A (https=)
AR (3) AR061842A1 (https=)
AT (1) ATE524447T1 (https=)
AU (1) AU2007269060B2 (https=)
BR (3) BR122013028005B8 (https=)
CA (2) CA2836316A1 (https=)
CL (1) CL2007001993A1 (https=)
CO (1) CO6150161A2 (https=)
CR (1) CR10600A (https=)
CY (1) CY1112117T1 (https=)
DK (2) DK2402325T3 (https=)
ES (3) ES2554228T3 (https=)
HR (1) HRP20110908T1 (https=)
HU (1) HUE026237T2 (https=)
IL (2) IL196028A (https=)
IN (1) IN2014KN02886A (https=)
MA (1) MA31655B1 (https=)
MX (4) MX377920B (https=)
MY (1) MY147364A (https=)
NO (1) NO342346B1 (https=)
NZ (3) NZ597647A (https=)
PL (2) PL2402325T3 (https=)
PT (1) PT2049501E (https=)
RS (1) RS52212B (https=)
RU (2) RU2478632C2 (https=)
SG (4) SG10201802127UA (https=)
SI (2) SI2402325T1 (https=)
TW (2) TWI402266B (https=)
UA (1) UA95641C2 (https=)
WO (1) WO2008006040A1 (https=)
ZA (1) ZA200900070B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008115511A1 (en) 2007-03-20 2008-09-25 Peak Biosciences, Inc. Method for therapeutic administration of radionucleosides
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN102015708B (zh) 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CA2711782C (en) * 2008-01-09 2017-01-03 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
NZ586346A (en) * 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) * 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
WO2012087336A1 (en) * 2010-12-23 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
KR102021157B1 (ko) * 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
EP3617330B1 (en) * 2011-04-01 2023-12-27 Genentech, Inc. Biomarkers for predicting sensitivity to cancer treatments
HRP20200992T1 (hr) * 2012-05-17 2020-10-16 Genentech, Inc. Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci
MX350443B (es) 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
CN104471070B (zh) * 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
RU2014151017A (ru) 2012-05-17 2016-07-10 Аррэй Байофарма Инк. Способ получения гидроксилированных циклопентилпиримидинов
AU2013262505B2 (en) * 2012-05-17 2017-09-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
RU2015127037A (ru) * 2012-12-07 2017-01-11 Дзе Дженерал Хоспитал Корпорейшн Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
ES2765511T3 (es) 2013-11-15 2020-06-09 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
ES2749100T3 (es) * 2014-09-26 2020-03-19 Hoffmann La Roche Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
TWI777658B (zh) 2016-08-10 2022-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
CA3092677A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CN113194941A (zh) 2018-12-19 2021-07-30 基因泰克公司 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
PL3919491T3 (pl) 2019-01-29 2025-10-20 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor akt
WO2020201073A1 (en) 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
EP3952871A4 (en) * 2019-04-09 2023-06-07 Dana-Farber Cancer Institute, Inc. AKT DEGRADATION BY CONJUGATION OF ATP COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
TWI908780B (zh) * 2020-03-17 2025-12-21 大陸商江蘇恆瑞醫藥股份有限公司 稠合二環類衍生物、其製備方法及其在醫藥上的應用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
IL295929A (en) 2020-06-16 2022-10-01 Hoffmann La Roche Process for making hydroxylated cyclopentylpyrimidine compounds
CN115836069B (zh) 2020-07-22 2024-02-06 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
CN117677614A (zh) * 2021-12-17 2024-03-08 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
JP2026509089A (ja) 2023-01-31 2026-03-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ケトレダクターゼ活性が増加した変異型ケトレダクターゼならびにそれに関する方法および使用
EP4643858A1 (en) 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of uterine disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030546A1 (en) * 1997-01-08 1998-07-16 F. Hoffmann-La Roche Ag TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES
WO2001007397A1 (es) * 1999-07-27 2001-02-01 Medichem S.A. Procedimiento de obtencion de venlafaxina
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (https=) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AU8544901A (en) * 2000-08-18 2002-03-04 Cor Therapeutics Inc Quinazoline derivatives as kinase inhibitors
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2365905T3 (es) * 2001-03-30 2011-10-13 King Pharmaceuticals, Inc. Compuestos de tiofeno condensados y uso de los mismos en el tratamiento del dolor crónico.
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
JP4469179B2 (ja) * 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7531556B2 (en) * 2004-04-28 2009-05-12 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
CA2600745A1 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
EP2049500B1 (en) * 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030546A1 (en) * 1997-01-08 1998-07-16 F. Hoffmann-La Roche Ag TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES
WO2001007397A1 (es) * 1999-07-27 2001-02-01 Medichem S.A. Procedimiento de obtencion de venlafaxina
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors

Also Published As

Publication number Publication date
DK2402325T3 (en) 2015-12-07
MX2019008117A (es) 2019-09-04
EP2966065A2 (en) 2016-01-13
EP2402325B1 (en) 2015-08-26
CN102816124A (zh) 2012-12-12
EP2399909A1 (en) 2011-12-28
KR20130029364A (ko) 2013-03-22
EP2399909B1 (en) 2015-08-26
AR109424A2 (es) 2018-11-28
BR122013028005B8 (pt) 2021-05-25
DK2049501T3 (da) 2011-12-12
KR20090030333A (ko) 2009-03-24
IL241705A0 (en) 2015-11-30
CN101578273A (zh) 2009-11-11
JP2009542723A (ja) 2009-12-03
CR10600A (es) 2009-02-20
SI2402325T1 (sl) 2015-12-31
NZ610633A (en) 2014-12-24
EP2402325A3 (en) 2012-06-13
EP2049501B1 (en) 2011-09-14
CA2836316A1 (en) 2008-01-10
RU2012155606A (ru) 2014-06-27
KR101495408B1 (ko) 2015-02-25
MX377920B (es) 2025-03-11
TW200817373A (en) 2008-04-16
BR122013028012B8 (pt) 2021-05-25
EP2402325A2 (en) 2012-01-04
HK1160638A1 (en) 2012-08-10
MY147364A (en) 2012-11-30
SG10201802127UA (en) 2018-04-27
CN101578273B (zh) 2012-11-14
ES2554228T3 (es) 2015-12-17
BRPI0713923A2 (pt) 2013-07-02
MX2008016202A (es) 2009-02-11
JP5266216B2 (ja) 2013-08-21
CA2656622C (en) 2017-09-12
KR20130141717A (ko) 2013-12-26
KR101178672B1 (ko) 2012-09-07
PL2402325T3 (pl) 2016-01-29
TW201332994A (zh) 2013-08-16
IL196028A (en) 2017-02-28
MX366319B (es) 2019-07-05
EP2049501A1 (en) 2009-04-22
CY1112117T1 (el) 2015-11-04
HK1160134A1 (en) 2012-08-10
RU2478632C2 (ru) 2013-04-10
IL196028A0 (en) 2009-09-01
ATE524447T1 (de) 2011-09-15
JP2014231530A (ja) 2014-12-11
HRP20110908T1 (hr) 2012-02-29
RS52212B (sr) 2012-10-31
CA2656622A1 (en) 2008-01-10
RU2009103900A (ru) 2010-08-20
AR093810A2 (es) 2015-06-24
AU2007269060B2 (en) 2014-02-20
IN2014KN02886A (https=) 2015-05-08
SI2049501T1 (sl) 2012-01-31
SG188905A1 (en) 2013-04-30
SG185980A1 (en) 2012-12-28
BR122013028005B1 (pt) 2021-04-06
CO6150161A2 (es) 2010-04-20
MX337843B (es) 2016-03-22
HK1126768A1 (en) 2009-09-11
WO2008006040A1 (en) 2008-01-10
MA31655B1 (fr) 2010-09-01
HUE026237T2 (en) 2016-06-28
ES2554252T3 (es) 2015-12-17
ZA200900070B (en) 2010-03-31
NZ573732A (en) 2012-03-30
AU2007269060A1 (en) 2008-01-10
JP2013091670A (ja) 2013-05-16
PL2049501T3 (pl) 2012-02-29
TWI402266B (zh) 2013-07-21
NZ597647A (en) 2013-08-30
ES2372774T3 (es) 2012-01-26
BR122013028012B1 (pt) 2021-04-06
KR20140093291A (ko) 2014-07-25
BRPI0713923B1 (pt) 2020-09-29
UA95641C2 (xx) 2011-08-25
NO342346B1 (no) 2018-05-07
CL2007001993A1 (es) 2008-06-20
BRPI0713923B8 (pt) 2021-05-25
JP2013177470A (ja) 2013-09-09
AR061842A1 (es) 2008-09-24
PT2049501E (pt) 2011-12-30
KR20150051240A (ko) 2015-05-11
NO20090581L (no) 2009-04-06
JP5836294B2 (ja) 2015-12-24
SG184706A1 (en) 2012-10-30
EP2966065A3 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
KR101578877B1 (ko) ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR101527232B1 (ko) Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
US8063050B2 (en) Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5231410B2 (ja) Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロフロピリミジン
JP5231411B2 (ja) Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン
JP5542282B2 (ja) Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
KR20100044819A (ko) Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) Pyrimidyl cyclopentanes as AKT protein kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131129

Application number text: 1020127011042

Filing date: 20120427

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140326

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140626

Application number text: 1020127011042

Filing date: 20120427

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20141027

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150427

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141027

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20140326

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150728

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150427

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150911

Appeal identifier: 2015101004381

Request date: 20150728

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20150820

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20150728

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20141229

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20140626

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20150911

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20150902

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151210

Application number text: 1020127011042

Filing date: 20120427

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20151214

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20151215

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20181115

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20181115

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190924

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20201005

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20201005

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20210929

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20220921

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20220921

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20231128

Start annual number: 9

End annual number: 9